Home › Multilingual Archive Index › 1-(3-Chlorophenyl)piperazine

1-(3-Chlorophenyl)piperazine

1-(3-Chlorophenyl)piperazine (or meta-chlorophenylpiperazine, mCPP) is a piperazine-based 5-HT receptor agonist. In the mid-2000s, it has shown up in legal alternatives to illegal stimulants in New Zealand, and pills sold as ecstasy in Europe and the United States.

mCPP is known to induce headaches in humans,^[1][2] and has been used for testing potential anti-migraine medications.^[3] Up to 10% of people who take mCPP will develop a migraine headache, and 90% of individuals who commonly suffer from migraines will have an attack induced by mCPP. This has tended to limit the use of mCPP as a recreational drug.

Legal status

In the Netherlands: unscheduled
In the US: unscheduled
In Denmark: Banned ^[4]
In Germany: Banned
In Sweden: legal

Based on the recommendation of the EACD, the New Zealand government has passed legislation which placed BZP, along with the other piperazine derivatives TFMPP, mCPP, pFPP, MeOPP and MBZP, into Class C of the New Zealand Misuse of Drugs Act 1975. A ban was intended to come into effect in New Zealand on December 18th 2007, but the law change did not go through until the following year, and the sale of BZP and the other listed piperazines became illegal in New Zealand as of 1st of April 2008. An amnesty for possession and usage of these drugs will remain until October 2008, at which point they will become completely illegal.^[5]

See also

• Benzylpiperazine (BZP)
• Trifluoromethylphenylpiperazine (TFMPP)
• Etoperidone
• Trazodone -- metabolises to mCPP in vivo

References

1. ^ Leone, M; A Attanasio, D Croci, G Filippini, D D'Amico, L Grazzi, A Nespolo, G Bussone (July 12, 2000). "The serotonergic agent m-chlorophenylpiperazine induces migraine attacks: A controlled study". Neurology 55 (1): 136–9. PMID 10891925. 
2. ^ Martin RS & Martin GR. Investigations into migraine pathogenesis: time course for effects of m-CPP, BW723C86 or glyceryl trinitrate on appearance of Fos-like immunoreactivity in rat trigeminal nucleus caudalis (TNC). Cephalalgia 2001; 21:46–52. London. ISSN 0333-10245
3. ^ Petkov VD, Belcheva S, Konstantinova E. Anxiolytic effects of dotarizine, a possible antimigraine drug. Methods Find Exp Clin Pharmacol. 1995 Dec;17(10):659-68.
4. ^ Erowid.org
5. ^ Misuse of Drugs (Classification of BZP) Amendment Bill 2008

External links

• Erowid Vault
• EMCDDA-Europol Joint Report on 1-(3-chlorophenyl)piperazine (mCPP)